» Articles » PMID: 16921491

Prostate Cancer Stem/progenitor Cells: Identification, Characterization, and Implications

Overview
Journal Mol Carcinog
Date 2006 Aug 22
PMID 16921491
Citations 91
Authors
Affiliations
Soon will be listed here.
Abstract

Several solid tumors have now been shown to contain stem cell-like cells called cancer stem cells (CSC). These cells, although generally rare, appear to be highly tumorigenic and may be the cells that drive tumor formation, maintain tumor homeostasis, and mediate tumor metastasis. In this Perspective, we first provide our insight on how a CSC should be defined. We then summarize our current knowledge of stem/progenitor cells in the normal human prostate (NHP), an organ highly susceptible to hyperproliferative diseases such as benign prostate hyperplasia (BPH) and prostate cancer (PCa). We further review the evidence that cultured PCa cells, xenograft prostate tumors, and patient tumors may contain stem/progenitor cells. Along with our discussion, we present several methodologies that can be potentially used to identify putative tumor-reinitiating CSC. Finally, we present a hypothetical model for the hierarchical organization of human PCa cells and discuss the implications of this model in helping understand prostate carcinogenesis and design novel diagnostic, prognostic, and therapeutic approaches.

Citing Articles

TGM2-Mediated Autophagy Contributes to the Radio-Resistance of Non-Small Cell Lung Cancer Stem-like Cells.

Wang Q, Zhang Q, Wang X, Luo H, Du T, Wu L Biomedicines. 2024; 12(10).

PMID: 39457544 PMC: 11504678. DOI: 10.3390/biomedicines12102231.


SIX2 promotes cell plasticity via Wnt/β-catenin signalling in androgen receptor independent prostate cancer.

Leppanen N, Kaljunen H, Takala E, Kaarijarvi R, Makinen P, Yla-Herttuala S Nucleic Acids Res. 2024; 52(10):5610-5623.

PMID: 38554106 PMC: 11162805. DOI: 10.1093/nar/gkae206.


Therapeutic implications of cancer stem cells in prostate cancer.

Banerjee P, Kapse P, Siddique S, Kundu M, Choudhari J, Mohanty V Cancer Biol Med. 2023; 20(6).

PMID: 37282627 PMC: 10291985. DOI: 10.20892/j.issn.2095-3941.2022.0714.


Targeting aldehyde dehydrogenase for prostate cancer therapies.

Ma M, He W, Zhao K, Xue L, Xia S, Zhang B Front Oncol. 2022; 12:1006340.

PMID: 36300093 PMC: 9589344. DOI: 10.3389/fonc.2022.1006340.


Drug-Tolerant Persister Cells in Cancer Therapy Resistance.

Dhanyamraju P, Schell T, Amin S, Robertson G Cancer Res. 2022; 82(14):2503-2514.

PMID: 35584245 PMC: 9296591. DOI: 10.1158/0008-5472.CAN-21-3844.